IN8bio, Inc. Profile Avatar - Palmy Investing

IN8bio, Inc.

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologou…

Biotechnology
US, New York [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

IN8bio, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of INAB's Analysis
CIK: 1740279 CUSIP: 45674E109 ISIN: US45674E1091 LEI: - UEI: -
Secondary Listings
INAB has no secondary listings inside our databases.